OBJECTIVE: Determine the incidence of hepatitis C virus antibodies among a cohort of prisoners. DESIGN: Follow-up study of a random sample of prisoners who participated in a cross-sectional survey in 1996. SETTING: 29 correctional centres in New South Wales (Australia). PARTICIPANTS: 181 adult prisoners (163 men and 18 women). RESULTS: The incidence of hepatitis C virus antibody among the 90 inmates who were seronegative at the first test in 1996 was 7.1 per 100 person-years (16 seroconverters). Among the 90 inmates, 37 had re-entered the prison system following release into the community and 53 had been continuously detained. The seroconversion rate was higher among the re-entrants compared with those who had been continuously incarcerated (10.8 vs. 4.5 per 100 person-years, p=0.07). However, when the data was stratified by injecting status, the serocon-version rate in the two groups was similar. Most of the seroconverters had histories of injecting drug users (14/16). The overall incidence among injectors was 19.3 per 100 person years (95% CI: 9.1-29.2). CONCLUSIONS: Hepatitis C transmission occurs inside the prison with injecting drug use the likely cause. Among non-injectors, tattooing was the most likely mode of transmission. Harm minimisation measures with proven effectiveness need to be considered for this environment.
OBJECTIVE: Determine the incidence of hepatitis C virus antibodies among a cohort of prisoners. DESIGN: Follow-up study of a random sample of prisoners who participated in a cross-sectional survey in 1996. SETTING: 29 correctional centres in New South Wales (Australia). PARTICIPANTS: 181 adult prisoners (163 men and 18 women). RESULTS: The incidence of hepatitis C virus antibody among the 90 inmates who were seronegative at the first test in 1996 was 7.1 per 100 person-years (16 seroconverters). Among the 90 inmates, 37 had re-entered the prison system following release into the community and 53 had been continuously detained. The seroconversion rate was higher among the re-entrants compared with those who had been continuously incarcerated (10.8 vs. 4.5 per 100 person-years, p=0.07). However, when the data was stratified by injecting status, the serocon-version rate in the two groups was similar. Most of the seroconverters had histories of injecting drug users (14/16). The overall incidence among injectors was 19.3 per 100 person years (95% CI: 9.1-29.2). CONCLUSIONS: Hepatitis C transmission occurs inside the prison with injecting drug use the likely cause. Among non-injectors, tattooing was the most likely mode of transmission. Harm minimisation measures with proven effectiveness need to be considered for this environment.
Authors: D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy Journal: CMAJ Date: 2001-10-02 Impact factor: 8.262
Authors: M Malliori; V Sypsa; M Psichogiou; G Touloumi; A Skoutelis; N Tassopoulos; A Hatzakis; C Stefanis Journal: Addiction Date: 1998-02 Impact factor: 6.526
Authors: Hla-Hla Thein; Tony Butler; Murray Krahn; William Rawlinson; Michael H Levy; John M Kaldor; Gregory J Dore Journal: J Urban Health Date: 2006-03 Impact factor: 3.671
Authors: Bruno Fernandes de Oliveira Santos; Nathalie Oliveira de Santana; Alex Vianey Callado Franca Journal: World J Gastroenterol Date: 2011-07-07 Impact factor: 5.742
Authors: Marisol Peña-Orellana; Adriana Hernández-Viver; Glorimar Caraballo-Correa; Carmen E Albizu-García Journal: J Health Care Poor Underserved Date: 2011-08
Authors: Corina Lelutiu-Weinberger; Enrique R Pouget; Don D C Des Jarlais; Hannah L Cooper; Roberta Scheinmann; Rebecca Stern; Shiela M Strauss; Holly Hagan Journal: Soc Sci Med Date: 2008-12-04 Impact factor: 4.634
Authors: Ethan Gough; Mirjam C Kempf; Laura Graham; Marvin Manzanero; Edward W Hook; Al Bartolucci; Eric Chamot Journal: BMC Public Health Date: 2010-12-21 Impact factor: 3.295
Authors: Suzy Teutsch; Fabio Luciani; Nicolas Scheuer; Luke McCredie; Parastu Hosseiny; William Rawlinson; John Kaldor; Gregory J Dore; Kate Dolan; Rosemary Ffrench; Andrew Lloyd; Paul Haber; Michael Levy Journal: BMC Public Health Date: 2010-10-22 Impact factor: 3.295